|
GB1039113A
(en)
|
1964-08-06 |
1966-08-17 |
Ucb Sa |
New n-substituted lactams
|
|
GB1309692A
(en)
|
1970-02-13 |
1973-03-14 |
Ucb Sa |
N-substituted lactams
|
|
IT1045043B
(it)
*
|
1975-08-13 |
1980-04-21 |
Isf Spa |
Derivati pirrolidinici
|
|
IT1075280B
(it)
*
|
1977-02-11 |
1985-04-22 |
Isf Spa |
Procedimento per la preparazione di derivati pirrolidinici
|
|
BE864269A
(fr)
*
|
1977-03-03 |
1978-06-16 |
Parke Davis & Co |
Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
|
|
ATE27T1
(de)
*
|
1978-05-08 |
1981-04-15 |
Ucb Sa |
Lactam-n-essigsaeuren und ihre amide, verfahren zu ihrer herstellung und heilmittel, die sie enthalten
|
|
US4654370A
(en)
*
|
1979-03-12 |
1987-03-31 |
Abbott Laboratories |
Glyceryl valproates
|
|
US4372960A
(en)
*
|
1980-12-12 |
1983-02-08 |
Warner-Lambert Company |
Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
|
|
FR2515179A1
(fr)
*
|
1981-07-24 |
1983-04-29 |
Hoffmann La Roche |
Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
|
|
IL67623A
(en)
|
1983-01-05 |
1984-09-30 |
Teva Pharma |
1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
|
|
IL72381A
(en)
|
1983-07-20 |
1988-03-31 |
Sanofi Sa |
Pharmaceutical composition based on valproic acid
|
|
US4558070A
(en)
|
1983-10-26 |
1985-12-10 |
Abbott Laboratories |
Acid salts of valproic acid
|
|
GB8412357D0
(en)
|
1984-05-15 |
1984-06-20 |
Ucb Sa |
Pharmaceutical composition
|
|
GB8412358D0
(en)
|
1984-05-15 |
1984-06-20 |
Ucb Sa |
Pharmaceutical composition
|
|
US4668687A
(en)
*
|
1984-07-23 |
1987-05-26 |
Bristol-Myers Company |
Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
|
|
US4913906B1
(en)
*
|
1985-02-28 |
2000-06-06 |
Yissum Res Dev Co |
Controlled release dosage form of valproic acid
|
|
JPS6222785A
(ja)
*
|
1985-07-23 |
1987-01-30 |
Sanwa Kagaku Kenkyusho:Kk |
新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
|
|
IT1190133B
(it)
|
1986-06-19 |
1988-02-10 |
Chiesi Farma Spa |
Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
|
|
DE3709230A1
(de)
*
|
1987-03-20 |
1988-10-06 |
Desitin Arzneimittel Gmbh |
Neues calciumsalz der valproinsaeure
|
|
JPS6422883A
(en)
*
|
1987-07-17 |
1989-01-25 |
Sanwa Kagaku Kenkyusho Co |
1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
|
|
ES2026198T3
(es)
|
1987-07-22 |
1992-04-16 |
Farvalsa Ag |
Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion.
|
|
IL93051A0
(en)
|
1989-01-17 |
1990-11-05 |
Hoffmann La Roche |
((5-oxo-2-pyrrolidinyl)methyl)cyclohexaneacetamides,their preparation and pharmaceutical compositions containing them
|
|
FR2643556B1
(fr)
*
|
1989-02-27 |
1993-03-05 |
Sanofi Sa |
Composition pharmaceutique a liberation prolongee d'acide valproique
|
|
IT1231477B
(it)
*
|
1989-07-12 |
1991-12-07 |
Sigma Tau Ind Farmaceuti |
(pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
|
|
CA2067614C
(en)
*
|
1991-05-02 |
2002-07-30 |
Eiichi Otomo |
Agent for improving dementia
|
|
US5439930A
(en)
*
|
1992-04-14 |
1995-08-08 |
Russian-American Institute For New Drug Development |
Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
|
|
US5440023A
(en)
|
1992-09-18 |
1995-08-08 |
Beckman Instruments, Inc. |
Method for making valproic acid derivatives
|
|
GB9319732D0
(en)
*
|
1993-09-24 |
1993-11-10 |
Ucb Sa |
Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
|
|
US5468733A
(en)
|
1993-09-30 |
1995-11-21 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US5516759A
(en)
|
1994-12-08 |
1996-05-14 |
Tap Holdings Inc. |
LHRH antagonists having lactam groups at the N-terminus
|
|
IT1285801B1
(it)
|
1996-10-10 |
1998-06-24 |
Sigma Tau Ind Farmaceuti |
Procedimento migliorato per la preparazione dell'acido valproico
|
|
US6131106A
(en)
|
1998-01-30 |
2000-10-10 |
Sun Microsystems Inc |
System and method for floating-point computation for numbers in delimited floating point representation
|
|
US6620802B1
(en)
*
|
1999-11-23 |
2003-09-16 |
Corcept Therapeutics, Inc. |
Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
|
|
CA2475026A1
(en)
|
1999-12-01 |
2001-06-07 |
Ucb, S.A. |
A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
|
|
GB0004297D0
(en)
|
2000-02-23 |
2000-04-12 |
Ucb Sa |
2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
|
|
KR100823668B1
(ko)
*
|
2000-12-28 |
2008-04-21 |
해밀턴 파마슈티컬스 인코포레이티드 |
신경성 통증 치료 및 예방약
|
|
US6610326B2
(en)
|
2001-02-16 |
2003-08-26 |
Andrx Corporation |
Divalproex sodium tablets
|
|
US20040116505A1
(en)
*
|
2001-02-23 |
2004-06-17 |
Gregory Krauss |
Treatment of tics, tremors and related disorders
|
|
WO2002094787A1
(en)
|
2001-05-23 |
2002-11-28 |
Ucb, S.A. |
2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
|
|
CA2457982C
(en)
*
|
2001-08-22 |
2009-11-03 |
Daiichi Pharmaceutical Co., Ltd. |
Use of nefiracetam for treating neurodegeneration
|
|
CN1604776A
(zh)
|
2001-10-16 |
2005-04-06 |
记忆药物公司 |
作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物
|
|
US20040116506A1
(en)
*
|
2002-06-20 |
2004-06-17 |
Krusz John Claude |
Use of levetiracetam for treating or preventing acute headaches
|
|
US7557137B2
(en)
*
|
2002-08-05 |
2009-07-07 |
Bristol-Myers Squibb Company |
Gamma-lactams as beta-secretase inhibitors
|
|
JP2006516390A
(ja)
*
|
2002-12-03 |
2006-07-06 |
ユ セ ベ ソシエテ アノニム |
発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法
|
|
US7090985B2
(en)
*
|
2002-12-03 |
2006-08-15 |
Ucb, S.A. |
Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
|
|
ITMI20030573A1
(it)
*
|
2003-03-24 |
2004-09-25 |
Nikem Research Srl |
Composti ad azione nootropica, loro preparazione,
|
|
TW200508197A
(en)
|
2003-03-31 |
2005-03-01 |
Ucb Sa |
Indolone-acetamide derivatives, processes for preparing them and their uses
|
|
EA010031B1
(ru)
*
|
2003-12-02 |
2008-06-30 |
Юсб, С.А. |
Производные имидазола, способы их получения и применения
|
|
WO2005108358A2
(en)
|
2004-04-22 |
2005-11-17 |
Eli Lilly And Company |
Pyrrolidine derivatives useful as bace inhibitors
|
|
WO2005121082A1
(en)
|
2004-06-11 |
2005-12-22 |
Ucb, S.A. |
Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
|
|
WO2006034196A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Lifelike Biomatic Inc. |
Compositions for enhancing memory and methods therefor
|
|
EA014249B1
(ru)
*
|
2005-01-27 |
2010-10-29 |
Алембик Лимитед |
Формуляция леветирацетама длительного высвобождения
|
|
US20070298098A1
(en)
*
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
|
JP2008534522A
(ja)
*
|
2005-03-30 |
2008-08-28 |
ジェンファーム インク |
医薬組成物のための複合ステップ製造方法
|
|
EP2308870A3
(en)
|
2005-06-01 |
2011-10-19 |
UCB Pharma S.A. |
2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
|
|
EP1731149A1
(en)
*
|
2005-06-08 |
2006-12-13 |
Ucb S.A. |
Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
|
|
GB0517740D0
(en)
|
2005-08-31 |
2005-10-12 |
Novartis Ag |
Organic compounds
|
|
EP1963325A2
(en)
|
2005-12-07 |
2008-09-03 |
UCB Pharma, S.A. |
Xanthine derivatives, processes for preparing them and their uses
|
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
EP1991212A1
(en)
*
|
2006-03-08 |
2008-11-19 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
WO2007134077A2
(en)
*
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
|
US20080014271A1
(en)
*
|
2006-07-13 |
2008-01-17 |
Ucb, S.A. |
Novel pharmaceutical compositions comprising levetiracetam
|
|
WO2008021666A2
(en)
*
|
2006-08-18 |
2008-02-21 |
Morton Grove Pharmaceuticals, Inc. |
Stable liquid levetiracetam compositions and methods
|
|
WO2008095221A1
(en)
*
|
2007-02-07 |
2008-08-14 |
Gosforth Centre (Holdings) Pty Ltd |
Treatment of adhd
|
|
WO2008132142A2
(en)
|
2007-04-27 |
2008-11-06 |
Ucb Pharma S.A. |
New heterocyclic derivatives useful for the treatment of cns disorders
|
|
KR20090031333A
(ko)
|
2007-09-21 |
2009-03-25 |
주식회사 엘지생명과학 |
신규한 베타-세크리타제 저해용 화합물
|
|
US20090176740A1
(en)
|
2007-11-30 |
2009-07-09 |
Phillips Ii Dauglas James |
Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
|
|
MX2010009222A
(es)
*
|
2008-03-03 |
2010-09-28 |
Ucb Pharma Sa |
Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
|
|
JP2010024156A
(ja)
|
2008-07-16 |
2010-02-04 |
Ucb Pharma Sa |
レベチラセタムを含む医薬組成物
|
|
EP2331088A4
(en)
|
2008-08-06 |
2011-10-12 |
Gosforth Ct Holdings Pty Ltd |
COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
|
|
DK3260118T3
(da)
|
2008-10-16 |
2021-04-19 |
Univ Johns Hopkins |
Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
|
|
US9125898B2
(en)
*
|
2008-11-14 |
2015-09-08 |
Neurotune Ag |
Acetam derivatives for pain relief
|
|
AU2009317280B2
(en)
|
2008-11-18 |
2014-03-06 |
Ucb Pharma, S.A. |
Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
|
|
CN104906085A
(zh)
|
2009-01-29 |
2015-09-16 |
Ucb医药有限公司 |
含有2-氧代-1-吡咯烷衍生物的药物组合物
|
|
EP2393483B1
(en)
|
2009-02-09 |
2017-06-28 |
UCB Biopharma SPRL |
Pharmaceutical compositions comprising brivaracetam
|
|
WO2011015349A2
(en)
|
2009-08-07 |
2011-02-10 |
Ucb Pharma, S.A. |
Methods for enhancing the cognitive function
|
|
CA2986598C
(en)
*
|
2015-05-22 |
2023-09-26 |
Agenebio, Inc. |
Extended release pharmaceutical compositions of levetiracetam
|